Amersham International remains faithful to branded products
This article was originally published in Clinica
Executive Summary
Despite product setbacks during fiscal 1995, UK nuclear medicine specialist Amersham International continues to base future growth expectations on its higher-margin, branded imaging products. Such growth is reliant on regulatory progress and the successful exploitation of its marketing and distribution formulas, says CEO Bill Castell.